TIVICAY Drug Profile, 2023, TIVICAY (dolutegravir sodium) drug patents, FDA exclusivity, litigation, drug prices

TIVICAY Drug Profile, 2023, TIVICAY (dolutegravir sodium) drug patents, FDA exclusivity, litigation, drug prices

book image

TIVICAY Drug Profile, 2023

This report focuses on TIVICAY and covers the following critical aspects of this drug:

  • United States patents
  • FDA Paragraph IV patent challenges
  • District Court patent litigation
  • European supplementary protection certificates (SPCs)
  • Clinical trials
  • Drug prices
  • Finished product suppliers
  • Raw active pharmaceutical ingredient (API) sources

Read More

Leave a Reply

Your email address will not be published. Required fields are marked *